WASHINGTON — The Food and Drug Administration last month foisted a nearly impossible decision on insurers: Should they pay for an expensive new Alzheimer’s drug that may not actually help patients?
Normally, if a drug gets FDA approval, that means it has some benefit to patients. But the FDA decided to greenlight Biogen’s controversial drug Aduhelm without that guarantee.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
